Advertisement
Research Article

Drug-Tolerant Cancer Cells Show Reduced Tumor-Initiating Capacity: Depletion of CD44+ Cells and Evidence for Epigenetic Mechanisms

  • Hong Yan equal contributor,

    equal contributor Contributed equally to this work with: Hong Yan, Xin Chen, Qiuping Zhang

    Affiliations: Department of Molecular Carcinogenesis, the University of Texas M.D. Anderson Cancer Center, Smithville, Texas, United States of America, Wuhan University School of Public Health, Wuhan, Hubei, China

    X
  • Xin Chen equal contributor,

    equal contributor Contributed equally to this work with: Hong Yan, Xin Chen, Qiuping Zhang

    Affiliations: Department of Molecular Carcinogenesis, the University of Texas M.D. Anderson Cancer Center, Smithville, Texas, United States of America, Program in Molecular Carcinogenesis, The University of Texas Graduate School of Biomedical Sciences, Houston, Texas, United States of America

    X
  • Qiuping Zhang equal contributor,

    equal contributor Contributed equally to this work with: Hong Yan, Xin Chen, Qiuping Zhang

    Affiliations: Department of Molecular Carcinogenesis, the University of Texas M.D. Anderson Cancer Center, Smithville, Texas, United States of America, Department of Immunology, Wuhan University School of Basic Medical Science, Wuhan, Hubei, China

    X
  • Jichao Qin,

    Affiliation: Department of Molecular Carcinogenesis, the University of Texas M.D. Anderson Cancer Center, Smithville, Texas, United States of America

    X
  • Hangwen Li,

    Affiliation: Department of Molecular Carcinogenesis, the University of Texas M.D. Anderson Cancer Center, Smithville, Texas, United States of America

    X
  • Can Liu,

    Affiliation: Department of Molecular Carcinogenesis, the University of Texas M.D. Anderson Cancer Center, Smithville, Texas, United States of America

    X
  • Tammy Calhoun-Davis,

    Affiliation: Department of Molecular Carcinogenesis, the University of Texas M.D. Anderson Cancer Center, Smithville, Texas, United States of America

    X
  • Luis Della Coletta,

    Affiliation: Department of Molecular Carcinogenesis, the University of Texas M.D. Anderson Cancer Center, Smithville, Texas, United States of America

    X
  • Jim Klostergaard,

    Affiliation: Department of Molecular and Cellular Oncology, the University of Texas, M.D. Anderson Cancer Center, Houston, Texas, United States of America

    X
  • Izabela Fokt,

    Affiliation: Department of Experimental Therapeutics, the University of Texas, M.D. Anderson Cancer Center, Houston, Texas, United States of America

    X
  • Stanislaw Skora,

    Affiliation: Department of Experimental Therapeutics, the University of Texas, M.D. Anderson Cancer Center, Houston, Texas, United States of America

    X
  • Waldemar Priebe,

    Affiliation: Department of Experimental Therapeutics, the University of Texas, M.D. Anderson Cancer Center, Houston, Texas, United States of America

    X
  • Yongyi Bi,

    Affiliation: Department of Molecular Carcinogenesis, the University of Texas M.D. Anderson Cancer Center, Smithville, Texas, United States of America

    X
  • Dean G. Tang mail

    dtang@mdanderson.org

    Affiliations: Department of Molecular Carcinogenesis, the University of Texas M.D. Anderson Cancer Center, Smithville, Texas, United States of America, Program in Molecular Carcinogenesis, The University of Texas Graduate School of Biomedical Sciences, Houston, Texas, United States of America, Centers for Cancer Epigenetics, Stem Cell and Developmental Biology, RNA Interference and Non-coding RNAs, and Molecular Carcinogenesis, the University of Texas M.D. Anderson Cancer Center, Houston, Texas, United States of America

    X
  • Published: September 15, 2011
  • DOI: 10.1371/journal.pone.0024397

Reader Comments (0)

Post a new comment on this article